Regulatory Story
Go to market news section View chart   Print
RNS
Medica Group PLC  -  MGP   

Unaudited half year results

Released 07:00 12-Sep-2018

RNS Number : 4775A
Medica Group PLC
12 September 2018
 

 

12 September 2018

 

Medica Group PLC

Unaudited half year results for the six months ended 30 June 2018

Interim results delivering double digit growth

 

Medica Group PLC (LSE:MGP, "Medica", the "Company" or the "Group"), the UK market leader in the provision of teleradiology services, today announces its half year results for the six months ended 30 June 2018.

 

 

Six months ended 30 June 2018 (£000)

Six months ended 30 June 2017 (£000)

% change

Revenue

18,592

15,723

18.2%

Gross Profit

9,091

7,644

18.9%

Gross Profit Margin

48.9%

48.6%

 

EBITDA (1)

5,610

4,873

15.1%

EBITDA Margin

30.2%

31.0%

 

Adjusted Operating Profit (2)

4,990

4,325

15.4%

Adjusted EPS (pence) (3)

3.64

3.14

16.0%

 

(1)    Adjusted EBITDA is a non-IFRS measure and is calculated as operating profit before depreciation, amortisation, exceptional items, and share based payments.

(2)    Adjusted operating profit is a non-IFRS measure and is calculated as operating profit before exceptional items, certain exceptional costs relating to refinancing, share based payments and amortisation in respect of assets acquired on acquisition.

(3)    Adjusted earnings per share is a non-IFRS measure and is calculated as Earnings per share before exceptional items (including certain exceptional costs relating to refinancing), share based payments and amortisation in respect of assets acquired on acquisition

 

A reconciliation of non-statutory measures in included in note 6.

 

Financial highlights

·     Delivered revenue growth of 18.2%

NightHawk revenues grew strongly, increasing by 21.0% to £9.3m

Cross Sectional performed well, with revenue increasing by 19.6% to £7.0m

Plain Film revenues increased by 10.8% to £2.0m due to additional radiographer reporting

·     Gross profit margin was consistent at 48.9% (48.6% in 2017) as a result of positive contract phasing and volume mix

·     Adjusted operating profit increased by 15.4% to £5.0m

·     Net debt significantly reduced to £2.5m (2017: £8.5m)

 

 

Operational highlights

·     Total number of reported body parts increased by 16.4%

NightHawk and Cross Sectional reported body parts increased by 24.4% and 21.8% respectively, well ahead of market

Plain Film reported body parts increased by 12.0% due to an increase in radiographer reporting

·     Continued to recruit strongly and added a net 33 radiologists in the period, taking the total to 339 contracted radiologists (including radiographers and rheumatologists) as at 30 June 2018 (30 June 2017: 267)

 

 

Post period end

·     Strong recruitment since 30 June 2018, adding a further 7 radiologists, increasing the number of contracted radiologists to 346 as at 12 September 2018

 

 

John Graham, Chief Executive Officer of Medica, commented:

 

"Medica continued to deliver double-digit revenue growth in the first half of 2018 as we execute on our strategy to increase customer penetration of Nighthawk and Cross Sectional services. During the first six months of 2018, the Group has been investing in several medium- to long-term opportunities which will enable us to diversify our service offering and support growth.

 

We have continued to recruit radiologists to provide service to our customers and are confident that our capabilities can help our customers address the widely-reported radiologist shortage in the NHS.

 

Additionally, we continue to reduce net debt and expect this to be negligible by the year-end.

 

Overall, the Board expects the Company's performance for the full year to be in line with market expectations."

 

 

 

For further information, please contact:  

 

Medica Group:

+44 (0)33 33 111 222

John Graham, Chief Executive Officer

 

Tony Lee, Chief Financial Officer

 

 

 

Investec Bank plc

+44 (0)20 7597 5970

Sara Hale

Daniel Adams

 

Henry Reast

Edward Thomas

David Herring

 

 

 

FTI Consulting

+44 (0)20 3727 1000

Brett Pollard

 

Ben Atwell

 

Victoria Foster Mitchell

 

Robert Winder

 

 

 

 

 

 

INTERIM MANAGEMENT REPORT

 

Chairman's statement

 

I am pleased to present Medica Group PLC's interim financial statements for the six months to 30 June 2018.

 

A strategy for continued success

 

Medica continued to grow strongly in the first half of 2018, and achieved double-digit growth for both revenue (18%) and adjusted operating profit (15%).

 

The teleradiology market continued to develop and demand from clients grew strongly as NHS Trusts continued to face capacity pressure and seek efficient high quality clinical solutions.

 

Medica's strategy continues to be to provide the highest quality clinical services and to promote improvements in clinical quality across the NHS.  Medica's goal is to work in partnership with NHS Trusts and independent providers to reduce waiting times and improve patient outcomes.  Using this approach, we believe Medica can continue to lead the growth of teleradiology in the UK.

 

Medica has continued to perform well in the first half of the year. Volume growth has been consistently strong for the two main service lines, NightHawk and Cross Sectional, with the growth mainly coming from existing clients.  The Plain Film service has also grown as our strategy of developing the radiographer reporting service has been established and starts to deliver.

 

Providing a supportive environment to Medica's radiologists is a key factor in the continued success of the Group.  Medica has developed an industry leading Clinical Governance platform that is an important factor in recruiting and retaining radiologists.  Medica has a healthy pipeline of radiologists, increasing its cohort by 33 during the period, taking the total to 339 contracted radiologists (including radiographers and rheumatologists) as at 30 June 2018

 

Medica is investing in further developing its service offerings and improving operational effectiveness.  These initiatives include identifying opportunities for new technologies within our business e.g. the application of AI to support improvements in productivity and clinical standards.  Medica continues to invest to maintain the highest clinical standards and fast response times to our customers' needs.  We are also looking to increase our radiology capacity by building a global network of specialists to match our growing current and future business needs.

 

We are excited about the future and believe as the teleradiology sector grows Medica will continue to lead the market in terms of its clinical standards and service offerings.

 

Dividends

 

Medica proposes to pay an interim dividend of 0.75 pence per ordinary share on 26 October 2018 to shareholders on the register at 28 September 2018. 

 

Outlook

 

Momentum continues to build across the business as a result of increasing client engagement, alongside broadening the service offering to new and existing customers. Medica remains committed to investing in developing new services and recruiting new radiologists to meet the growing demand for our services. Medica's strong brand, growing customer base and track record position us well to achieve our growth targets and the Board expects the Company's performance for the full year to be in line with market expectations.

 

Roy Davis

Chairman

 

 

 

 

 

Financial and Business Review

 

Introduction

 

Medica is the UK market leader in the provision of teleradiology services.  The Group currently has one business segment of teleradiology offering three primary services to hospital radiology departments: NightHawk, Routine Cross Sectional (Routine CS) and Routine Plain Film (Routine PF).

 

NightHawk is an out of hours emergency reporting service which is focused on delivering accurate reports within fast turnaround times and represents Medica's largest revenue contributor. NightHawk typically provides reporting on CT scans. The second and third key service offerings, Routine CS and Routine PF, are designed to assist hospital radiology departments in managing their demand/supply imbalance for less urgent daytime reporting on examinations. Routine CS covers a combination of CT and MRI scans (both forms of cross sectional scan) while Routine PF covers plain film examinations and both services typically have a 48 hour turnaround time.

 

Overview of performance in 2018

 

Medica, once again, showed strong double-digit growth in H1 2018. The Group recorded revenue of £18.6m for the first six months of the year, an increase of 18.2% on the equivalent period of 2017.  This growth was driven by volume growth in all main service lines.

 

Gross profit margin remained stable at 48.9% from 48.6% in H1 2017.  While gross profit margin was maintained in the first half of the year it is expected, as highlighted in the 2017 full year results, to reduce in the second half of the year and into 2019.  This reflects the on-going renewal of the Group's contracts at marginally lower prices because of the development of the teleradiology market and the opening up of outsourcing. The reduction in gross profit margin is expected to be more than offset by volume increases.

 

Medica has continued to invest in the business for the future, ensuring there is continued growth in staff and systems.  Administrative costs have grown by 21% from the comparative period partly due to the full period effect of the costs of being a PLC.  Accordingly, adjusted EBITDA margin has moved to 30.2% for the period to 30 June 2018 (30 June 2017: 31.0%). Operating profit for the period was £5.0m, 15.4% higher than for the period to 30 June 2017, which represents continuing good progress for the business.

 

Service lines

 

NightHawk

NightHawk continued to be Medica's largest service line, with H1 2018 revenue of £9.3m representing 50% of the total (H1 2017: 49%). 

 

Revenue growth in H1 2018 from the comparative period was 21.0%, with the volume of reported body parts increasing by 24.4%.  The gross profit margin remained consistent at 50.4% from 50.3%.

 

The majority of the growth has continued to come from increased emergency service requirements from existing clients as Medica's builds its partnerships with NHS Trusts and continues to improve its service.

 

Routine Cross Sectional

Routine Cross Sectional (CT and MR) contributed H1 2018 revenue of £7.0m, representing 38% of the total (H1 2017: 37%). 

 

Revenue growth in H1 2018 from the comparative period was 19.6%, with the volume of reported body parts increasing by 21.8%.  The gross profit margin remained consistent at 51.8% from 51.9%.

 

The majority of the growth has come from increased collaboration with existing clients as NHS Trusts consider Medica a key part of their capacity structure.

 

Routine Plain Film

The development of the radiographer reporting service has reversed the decline in the plain film service line.  Revenue of £2.0m represents 11% of the total (2017: 12%).

 

Revenue growth in H1 2018 from the comparative period was 10.8%, with the volume of reported body parts increasing by 12.0%.  The gross profit margin remained consistent at 49.2% from 49.3%.

 

Radiographer reporting represented 21.1% of total plain film volume (2017: 9.5%) and capacity is expected to continue to build.

 

Other service lines

A strategic objective for the business is to increase revenue from specialist service lines and independent healthcare providers.  There has not been growth in existing specialist services so far in 2018 with specialist services and independent revenue decreasing by 19.7% to £0.3m. New services are being strategically developed based on expected new demand due to changes in clinical guidelines and the introduction of Cardiac and MR Prostate reporting services are expected to make a contribution next year.

 

Earnings per share

 

Adjusted earnings per share increased by 16.0% to 3.64p, reflecting the continuing growth in the business.

 

Cash flow and net debt

 

The adjusted cash inflow from operating activities was £6.1m compared to £3.6m for the comparative period. The adjusted EBITDA cash conversion of 108.7% is higher (30 June 2017: 73.7%) due to strong cash collection at the end of the period and timing differences.

 

Net debt as at 30 June 2018 was £2.5m, compared to £8.5m as at 30 June 2017 as the business continues to generate strong cashflows. 

 

Fixed asset investment

 

The majority of tangible expenditure was expansionary costs of radiologist equipment and client infrastructure.  This represented £0.5m of the £0.6m spent on tangible additions.  Intangible additions of £0.2m relate to software purchases and developments.

 

Recruitment

 

Medica increased its number of contracted radiologists by 33 net in the period to 339 as at 30 June 2018.  The comparative figure for the first six months of 2017 is 19.  As at 12 September, the number was 346 and the second half of the year is expected to be as strong as the first. 

 

Recruitment and retention of radiologists is key to business growth and is core to Medica's strategy.  In broader terms, increasing capacity is more than numbers of radiologists and the strategy includes obtaining greater commitment from existing radiologists and improving productivity.

 

People

 

Medica's employees remain core to the quality of the service offering to clients and we will continue to recruit high calibre individuals as we grow.  We continue to recruit high calibre people into the business and employee numbers rose from 88 to 98 in the period.

 

We would like to thank our employees for their hard work, enthusiasm and dedication through a successful period of growth and change.

 

Forward looking statements

 

Certain statements in this interim report are forward looking.  Although the Board believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct.  Because these statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements.

 

Principal risks and uncertainties

 

The principal risks and uncertainties that could have a material impact on the Group's performance together with the mitigation strategies adopted have been reviewed and have not changed significantly from those set out on pages 23 to 24 of the Strategic Report included in the Groups 2017 Annual Report and Financial Statements.

 

These risks and uncertainties arise from:

·      Retaining and growing reporting capacity

·      Quality deficiencies or other issues affecting the Group's accreditations

·      Clinical quality

·      Failure to retain key management

·      Future changes in healthcare regulation

·      Reduction in demand for the Group's services from NHS Trusts

·      Failure to adequately protect its customers' patients' personal data

·      Significant competition and pricing pressure

·      Artificial Intelligence

·      Failure of information systems

 

 

 

 

 

John Graham, Chief Executive

 

Tony Lee, Chief Financial Officer

12 September 2018

 

12 September 2018

 

 

 

 

 

Condensed Consolidated Income Statement and Condensed Consolidated statement of comprehensive income

 

For the six months ended 30 June 2018

 

 

 

Unaudited

Unaudited

Audited

 

 

6 Months ended - 30

 6 Months ended - 30

12 months ended - 31

 

Note

June

2018

June

2017

 December

2017

 

 

£000

£000

£000

 

 

 

 

 

Revenue

3

18,592

15,723

33,715

Cost of sales

 

(9,501)

(8,079)

(17,282)

Gross profit

 

9,091

7,644

16,432

 

 

 

 

 

Administration expenses

 

(4,601)

(3,791)

(7,917)

Operating profit

 

4,490

3,853

8,516

 

 

 

 

 

Other expenses - exceptional items

4

-

(1,503)

(1,661)

Operating profit after exceptional items

 

4,490

2,350

6,855

 

 

 

 

 

Finance income

 

18

5

50

Finance costs

 

(154)

(483)

(661)

Exceptional items finance costs

4

-

(582)

(582)

Net finance costs

 

(136)

(1,060)

(1,193)

 

 

 

 

 

Profit before tax

 

4,354

1,290

5,662

 

 

 

 

 

Analysed as

 

 

 

 

Adjusted EBITDA

 

5,610

4,873

10,582

Share based payments

 

(65)

(37)

74

Exceptional items

4

-

(1,503)

(1,661)

Exceptional finance costs

4

-

(582)

(582)

Finance costs

 

(154)

(483)

(661)

Finance income

 

18

5

50

Depreciation

 

(420)

(387)

(775)

Amortisation

 

(635)

(596)

(1,217)

Profit before tax

 

4,354

1,290

5,662

 

Income tax charge

 

(807)

 

(510)

(1,331)

 

 

 

 

 

Profit attributable to equity holders of the parent

 

3,547

780

4,331

 

 

 

 

 

Statement of Comprehensive Income

 

 

 

 

 

Profit for the period/ year

 

3,547

 

780

4,331

Other comprehensive income

 

-

-

-

 

 

 

 

 

Total comprehensive profit for the period/ year attributable

to owners of the parent

3,547

 

780

4,331

 

Profit per share (basic and diluted)

 

 

 

 

Basic profit per ordinary share (pence)

5

3.19

0.73

3.99

Diluted profit per ordinary share (pence)

5

3.18

0.73

3.96

 

 

 

 

 

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheet

 

As at 30 June 2018

 

 

 

 

Unaudited

Unaudited

Audited

 

 

 

30

30

31

 

 

 

June

2018

June

2017

December

2017

 

 

 

£000

£000

£000

 

 

 

 

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

Goodwill

 

 

15,948

15,948

15,948

Other intangible assets

 

 

8,780

9,664

9,218

Property, plant and equipment

 

 

2,022

2,064

1,880

 

 

 

 

26,750

27,676

27,046

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Trade and other receivables

 

 

 

8,177

7,440

8,210

Cash and cash equivalents

 

 

 

9,366

3,390

6,907

 

 

 

 

17,543

10,830

15,117

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Trade and other payables

 

 

 

(3,839)

(3,188)

(3,932)

Derivative financial instruments

 

 

 

-

(29)

(14)

 

 

 

 

(3,839)

(3,217)

(3,946)

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

Borrowings and other financial liabilities

 

 

 

(11,900)

(11,876)

(11,888)

Deferred tax

 

 

 

(1,264)

(1,490)

(1,429)

 

 

 

 

(13,164)

(13,366)

(13,317)

 

 

 

 

 

 

 

Net assets

 

 

 

27,290

21,923

24,900

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

Share capital

 

 

 

222

222

222

Share premium

 

 

 

14,721

14,721

14,721

Retained profit

 

 

 

12,347

6,980

9,957

Total equity

 

 

 

27,290

21,923

24,900

 

 

 

 

 

 

 

 

 

 

 

 

Condensed Consolidated Statement of Changes in Equity

 

As at 30 June 2018

 

 

 

 

Share

Capital

Share

premium

Retained

earnings

Total

Equity

 

 

£000

£000

£000

£000

 

 

 

 

 

 

 

 

 

 

 

 

At 1 January 2017

 

146

1,309

4,854

6,309

 

 

 

 

 

 

 

 

 

 

 

 

Cancellation of share premium

 

-

(1,309)

1,309

-

Shares issued during the year

 

76

14,924

-

15,000

Share issue costs

 

-

(203)

-

(203)

Equity settled share based payments

-

-

37

37

Transactions with owners

 

76

13,412

1,346

14,834

 

 

 

 

 

 

Profit and total comprehensive income for the period

-

780

780

 

 

 

 

 

 

At 1 July 2017

 

222

14,721

6,980

21,923

 

 

 

 

 

 

 

 

 

 

 

 

Dividends paid to ordinary shareholders

 

-

-

(611)

(611)

Equity settled share based payments

-

-

37

37

Transactions with owners

 

-

-

(574)

(574)

 

 

 

 

 

 

Profit and total comprehensive income for the period

 

-

-

3,551

3,551

 

 

 

 

 

 

 

 

 

 

At 1 January 2018

 

222

14,721

9,957

24,900

 

 

 

 

 

 

Equity settled share based payments

 

 

65

65

Dividends paid to ordinary shareholders

-

-

(1,222)

(1,222)

Transactions with owners

 

-

-

(1,157)

(1,157)

 

 

 

 

 

 

Profit and total comprehensive income for the period

 

-

-

3,547

3,547

 

 

 

 

 

 

 

 

 

 

At 30 June 2018

 

222

14,721

12,347

27,290

 

 

 

 

 

 

 

 

 

 

 

Condensed Consolidated Cash Flow Statement

 

For the six months ended 30 June 2018

 

 

Unaudited

Unaudited

Audited

 

 6 Months ended

30 June

2018

6 Months ended

30 June

2017

12 Months ended 31

 December

2017

 

£000

£000

£000

Operating activities

 

 

 

Profit before tax

4,354

1,290

5,662

Adjustments for :

 

 

 

Depreciation

420

387

775

Amortisation

635

596

1,217

Share based payments

65

37

74

Finance income

(18)

(5)

(12)

Exceptional finance costs

-

-

582

Finance costs

168

1,088

661

 

 

 

 

Changes in:

 

 

 

Decrease / (Increase) in trade and other receivables

34

(1,367)

(2,138)

Increase / (Decrease) in trade and other payables

454

(529)

(365)

Movement of derivative financial instruments

(14)

(23)

(38)

Tax paid

(1,100)

(604)

(904)

Cash inflow from operating activities

4,998

870

5,514

 

 

 

 

Investing activities

 

 

 

Purchase of property plant and equipment

(571)

(616)

(820)

Purchase of software intangibles

(608)

(437)

(612)

Interest received

18

5

12

Cash outflow from investing activities

(1,161)

(1,048)

(1,420)

 

 

 

 

Cash flows from financing activities

 

 

 

Equity funds raised

-

15,000

15,000

Costs of equity funds raised

-

(203)

(203)

Repayment of borrowings

-

(15,270)

(15,270)

Loan fees paid for financing

-

(130)

(130)

Interest paid

(156)

(542)

(686)

Dividends paid to ordinary shareholders

(1,222)

-

(611)

Net cash outflow from financing

(1,378)

(1,145)

(1,900)

 

 

 

 

Net change in cash and cash equivalents

2,459

(1,323)

2,194

 

 

 

 

Movement in net cash

 

 

 

Cash and cash equivalents, beginning of period

6,907

4,713

4,713

 

 

 

 

(Decrease)/Increase in cash and cash equivalents

2,459

(1,323)

2,194

 

 

 

 

Cash and cash equivalents, end of period

9,366

3,390

6,907

 

 

 

 

 

 

 

 

 

Condensed notes to the accounts

 

1.   General Information

Medica Group PLC ("the Company") is incorporated in England and Wales.  The half-year results and condensed consolidated financial statements for the six months ended 30 June 2018 (the interim financial statements) comprise the results of the company and its subsidiaries (together referred to as the Group).

 

The Directors of Medica Group PLC have assessed the current financial position of the Group, along with future cash flow requirements to determine if the Group has the financial resources to continue as a going concern for a period of at least twelve months from the approval of the interim financial statements.  As a result of this review the Directors of Medica Group PLC have concluded that it is appropriate that Medica Group PLC be considered a going concern. For this reason, they have adopted the going concern basis in preparing the financial statements. The financial statements do not include any adjustments that would result in the going concern basis of preparation being inappropriate.

 

A copy of the statutory accounts for the year ended 31 December 2017 has been delivered to the Registrar of Companies. The auditors reported on those accounts: their report was unqualified, did not draw attention to any matters by way of emphasis and did not contain a statement under section 498 (2) or (3) of the Companies Act 2006.

 

The interim financial statements for the six months ended 30 June 2018 have been reviewed by Grant Thornton UK LLP but have not been audited.

 

2.   Accounting policies

 

Basis of preparation

The interim financial statements of Medica Group plc are prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting", the recognition and measurement criteria of International Financial Reporting Standards (IFRS) as adopted by the European Union and the disclosure requirements of the Listing Rules. The interim financial statements do not include all information required for full annual financial statements and should be read in conjunction with the Annual Report and Financial Statements for the year ended 31 December 2017.

 

Significant accounting policies

The accounting policies applied by the Group in this condensed set of consolidated financial statements are consistent with those applied by the Group in its consolidated financial statements for the year ended 31 December 2017. In additional the accounting policies used are consistent with those that the directors intend to use in the Annual Report and Financial Statements for the year ending 31 December 2018.  Taxes on income in the interim period are accrued using the tax rate that would be applicable to the expected total annual earnings.

 

Adoption of new and revised standards

 

With effect from 1st January 2018, IFRS 15 "Revenue from contracts with customers" has been adopted as explained in the Annual Report for the year ended 31st December 2017.  The new standard has not had a material impact on group revenue or earnings as previously stated.

 

With effect from 1st January 2018, IFRS 9 "Financial instruments" has been adopted as explained in the Annual Report for the year ended 31st December 2017.  The new standard has not had a material impact on the group's measurement of financial instruments.

 

At the date of authorisation of these interim financial statements, IFRS 16 'Leases' has been published by the IASB and adopted by the EU but is not yet effective, and has not been adopted early by the Group. Management anticipates that IFRS 16 will be adopted in the Group's accounting policies for the first period beginning after the effective date of the pronouncement.

 

IFRS 16 will impact the measurement and disclosure of lease liabilities, and the liabilities shown on the Group's balance sheet.  Management are in the process of completing a comprehensive review of IFRS 16 and will report the impact in the Group's Annual Report for the year ended 31st December 2018.

 

A number of IFRS and IFRIC interpretations are also currently in issue which are not relevant for the Group's activities and which have not therefore been adopted in preparing these financial statements.

 

3.         Segment reporting

 

Management prepare and monitor financial information for the Group's three primary service lines (Routine Cross-Sectional, Routine Plain Film and NightHawk) on a regular basis. This financial information is reviewed and used by the chief operational decisions maker (considered to be the Chief Executive Officer) in managing the operating activities of the Group. IFRS 8 sets out certain thresholds in determining whether reportable operating segments exist, and all of the three primary service lines exceed these thresholds. However, IFRS 8 permits the aggregation of operating segments where these services lines are similar in nature, service delivery processes, types or classes of customers, and regulatory factors. Management consider it is most appropriate to aggregate the three service lines into one teleradiology operating segment due to the similarities in respect of these factors.

 

Medica Group PLC has identified only one geographic area, the UK. As a result of this and there being only one operating segment as described above, no analysis has been provided.

 

No customer accounted for more than 10% of the Group's revenues. 

 

The Group identified four revenue streams, NightHawk, Routine Cross-Sectional, Routine Plain Film and other.  The analysis of revenue by each stream is detailed below.

 

 

 

 

 

 

 

 

Unaudited

Unaudited

Audited

 

 

 6 Months ended

30 June

2018

6 Months ended

30 June

2017

12 Months ended 31

 December

2017

 

 

 

 

 

NightHawk

 

9,293

7,683

16,798

Routine Cross-Sectional

 

6,973

5,830

12,542

Routine Plain Film

 

2,008

1,813

3,665

Other

 

318

397

710

 

 

18,592

15,723

33,715

 

 

4.         Exceptional items

 

 

Unaudited

Unaudited

Audited

 

 

 6 Months ended

30 June

2018

6 Months ended

30 June

2017

12 Months ended 31

 December

2017

 

 

 

 

 

Costs incurred in respect of Initial public offering

-

1,503

1,661

Capitalised debt fees written off

 

-

582

582

 

 

-

2,085

2,243

 

 

Exceptional items are items that are unusual because of their size and incidence and which the Directors consider should be separately disclosed to enable a full understanding of the Group's results.

  

 

5.         Earnings per share

 

Both the basic and diluted profit per share have been calculated using the profit after tax attributable to shareholders of Medica Group PLC as the numerator.  The calculation of the basic profit per share is based on the profit attributable to ordinary shareholders divided by the weighted average number of shares in issue during the year.

 

 

 

Unaudited

Unaudited

Audited

 

 6 Months ended

30 June

2018

6 Months ended

30 June

2017

12 Months ended 31

 December

2017

 

£000

£000

£000

 

 

 

 

Profit for the year attributable to ordinary shareholders

3,547

780

4,331

 

 

 

 

Exceptional items

-

1,503

1,661

Exceptional finance costs

-

582

582

Amortisation of acquired intangibles

435

435

870

Share based payments charge

65

37

74

 

 

 

 

Adjusted profit for the period attributable to ordinary shareholders

4,047

3,337

7,518

 

 

 

 

Weighted average number of ordinary shares

111,111,114

106,200,125

108,675,802

Dilutive effect of share options

500,129

372,222

746,264

Weighted average number of ordinary shares including dilutive

111,611,243

106,572,347

109,422,066

 

 

 

 

Basic profit per ordinary share (pence)

3.19

0.73

3.99

Diluted profit per ordinary share (pence)

3.18

0.73

3.96

Adjusted basic profit per ordinary share (pence)

3.64

3.14

6.92

Adjusted diluted basic profit per ordinary share (pence)

3.63

3.13

6.87

 

 

 

 

 

6.         Reconciliation of Non-IFRS Financial KPIs

The Group uses a number of key performance indicators to monitor the performance of its business.  This note reconciles these key performance indicators to individual lines in the financial statements.

 

 

6 Months

6 Months

12 Months

 

 ended 30

June

 2018

 ended 30

June

 2017

ended 31

 December

2017

Reconciliation of Adjusted Operating Profit

£

£

£

 

Operating profit

4,490

 

3,853

8,516

Adjustments for :

 

 

 

Amortisation of acquired intangibles

435

435

870

Equity settled share based payments

65

37

74

Adjusted Operating profit

4,990

4,325

9,460

 

 

 

 

Adjusted Operating profit margin

26.8%

27.5%

28.1%

 

 

 

 

Reconciliation of Adjusted Profit Before Tax

 

 

 

 

Profit for the year

3,547

 

780

4,331

Adjustments for :

 

 

 

Amortisation of acquired intangibles

435

435

870

Exceptional items

-

1,503

1,661

Exceptional finance costs

-

582

582

Share based payments

65

37

74

Adjusted profit after tax

4,047

3,337

7,518

 

 

 

 

Income tax charge

807

510

1,331

Adjusted Profit before Tax

4,854

3,847

8,849

 

 

Reconciliation of Adjusted EBITDA cash conversion percentage

 

 

 

 

Cash inflow from operating activities

4,998

 

870

5,514

Adjustments for :

 

 

 

Tax paid

1,100

604

904

Exceptional items

-

1,503

1,661

Non cash movement in exceptional items

-

612

612

 

6,098

3,589

8,691

 

 

 

 

Adjusted EBITDA

5,610

4,873

10,582

 

Conversion rate

107.7%

 

73.7%

82%

 

 

Reconciliation of Net debt

 

 

 

 

Cash and equivalents

9,366

3,390

6,907

Borrowings due after one year

(11,900)

(11,876)

(11,888)

 

Net Debt

         (2,534)

         (8,486)

        (4,981)

 

 

 

 

 

 

7.         Related party Transactions

 

Included in administrative costs are £21,000 (2017: £21,000) in respect of fees payable to CBPE Nominees Limited for the services of Anand Jain to the Group.

 

 

 

 

 

Statement of Directors' Responsibilities

The Directors confirm to the best of their knowledge that

 

(a)  The interim condensed consolidated financial information has been prepared in accordance with IAS 34 as adopted by the European Union; and

 

(b)  The Interim Report includes a fair view of the information as required by:

 

·      DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of important events that have occurred during the first half of 2018 and their impact on the interim condensed consolidated financial information; and a description of the principal risks and uncertainties for the remaining second half of the year; and

 

·      DTR4.2.8R of the Disclosure Guidance and Transparency Rules, being related party transactions that have taken place in the first half of 2018 and any material changes in the related party transactions described in the last Annual Report.

 

The Directors of Medica Group PLC and their functions are listed below:

 

Roy Davis - Chairman

John Graham - Chief Executive

Stephen Davies - Medical Director

Tony Lee - Chief Financial Officer

Steve Whittern - Senior Non-Executive Director

Anand Jain - Non-Executive Director

Michael Bewick - Non-Executive Director

 

 

By order of the Board

 

 

 

 

 

 

Tony Lee

Chief Financial Officer

12 September 2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Independent review report to the members of Medica Group plc

 

Introduction

We have reviewed the condensed set of financial statements in the half-yearly financial report of Medica Group plc for the six months ended 30 June 2018 which comprises the Condensed Consolidated Income Statement, the Condensed Consolidated Statement of Comprehensive Income, the Condensed Consolidated Balance Sheet, the Condensed Consolidated Statement of Changes in Equity, the Condensed Consolidated Cash Flow Statement and the related notes.  We have read the other information contained in the half yearly financial report which comprises only the Chairman's Statement and the Financial and Business Review and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.

 

This report is made solely to the company's members, as a body, in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity'. Our review work has been undertaken so that we might state to the company's members those matters we are required to state to them in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our review work, for this report, or for the conclusion we have formed.

 

Directors' responsibilities

The half-yearly financial report is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the half-yearly financial report in accordance with the Disclosure and Transparency Rules of the United Kingdom's Financial Conduct Authority.

 

As disclosed in note 2, the annual financial statements of the group are prepared in accordance with International Financial Reporting Standards as adopted by the European Union. The condensed set of financial statements included in this half-yearly financial report has been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union.

 

Our responsibility

Our responsibility is to express a conclusion on the condensed set of financial statements in the half-yearly financial report based on our review.

 

Scope of review

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

 

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2018 is not prepared, in all material respects, in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union and the Disclosure and Transparency Rules of the United Kingdom's Financial Conduct Authority.

 

 

 

 

 

GRANT THORNTON UK LLP
STATUTORY AUDITOR, CHARTERED ACCOUNTANTS

 

London

12 September 2018

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IR SFUFAFFASEFU
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Unaudited half year results - RNS